Analysts Set Expectations for RAPT FY2026 Earnings

RAPT Therapeutics, Inc. (NASDAQ:RAPT) – Analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of RAPT Therapeutics in a research note issued to investors on Monday, March 10th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.91) for the year. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.14) per share.

A number of other analysts have also issued reports on RAPT. Stifel Nicolaus restated a “hold” rating and issued a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. Wells Fargo & Company dropped their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $5.29.

RAPT Therapeutics Stock Performance

RAPT Therapeutics stock opened at $1.14 on Tuesday. RAPT Therapeutics has a 52 week low of $0.79 and a 52 week high of $9.65. The firm has a market capitalization of $39.85 million, a price-to-earnings ratio of -0.41 and a beta of -0.31. The company has a 50 day moving average price of $1.23 and a 200 day moving average price of $1.53.

RAPT Therapeutics (NASDAQ:RAPT) last announced its earnings results on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.69).

Hedge Funds Weigh In On RAPT Therapeutics

A number of hedge funds have recently modified their holdings of RAPT. Picton Mahoney Asset Management boosted its position in RAPT Therapeutics by 994.4% during the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock valued at $26,000 after purchasing an additional 14,697 shares during the last quarter. Readystate Asset Management LP acquired a new stake in shares of RAPT Therapeutics during the 3rd quarter valued at about $36,000. Los Angeles Capital Management LLC grew its stake in shares of RAPT Therapeutics by 9.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company’s stock valued at $348,000 after buying an additional 18,558 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after buying an additional 25,130 shares during the last quarter. Finally, Barclays PLC raised its position in RAPT Therapeutics by 277.2% during the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after acquiring an additional 29,195 shares in the last quarter. 99.09% of the stock is owned by institutional investors and hedge funds.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.